Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn
Lupin, India’s No. 2 drugmaker, spins-out two oncology programmes to Kaveri | Photo Credit: Reuters Global pharma major Lupin has spun-out two oncology programmes to Kaveri Therapeutics Inc for $1..6 million, taking its stake in the U.S. clinical-stage oncology company to 82.2%. Its wholly-owned US subsidiary Lupin Inc (LI), which has entered into a licensing…
Read More “Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn” »